Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Specialised Therapeutics licenses CanariaBio’s ovarian cancer antibody
Pharmaceutical Technology
OCTOBER 13, 2023
Specialised Therapeutics has entered an agreement to license Korea-based CanariaBio’s oregovomab for treating ovarian cancer.
Licensing 
130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront
Pharmaceutical Technology
FEBRUARY 28, 2024
AbbVie will pay $48m in upfront costs and up to $665m in milestone payments to license OSE’s monoclonal antibody OSE-230.
Licensing 130
130 
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current Good Manufacturing Practices (cGMP) compliant manufacturing facility in Deeside, UK.
Licensing 130
130 
Almirall and EpimAb partner to develop bispecific antibody therapies
Pharmaceutical Technology
OCTOBER 12, 2023
Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.
Antibody 147
147 
LegoChem partners Glycotope to develop antibody-drug conjugate
Pharmaceutical Technology
OCTOBER 17, 2023
LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).
Antibody 130
130 
BioNTech licenses bispecific antibody for cancer in $1 billion deal
BioPharma Reporter
NOVEMBER 7, 2023
The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech companyâs bispecific antibody cancer drug PM8002 in all territories except for Greater China.
Antibody 98
98 
Biogen licenses Denali’s amyloid beta programme for Alzheimer’s
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. ATV: Aβ uses Denali’s ATV technology to cross the blood-brain barrier (BBB) and increase brain exposure to antibodies.
Licensing 130
130 
AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.
Antibody 264
264 
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
Bio Pharma Dive
MAY 25, 2023
Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.
Antibody 310
310 
AbbVie announces acquisition of DJS Antibodies for $255m
Pharmaceutical Technology
OCTOBER 21, 2022
AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
Antibody 217
217 
US FDA approves Eisai-Biogen’s antibody for Alzheimer’s
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
FDA Approval 246
246 
Renaissance Pharma licenses Hu14.18 for neuroblastoma
Drug Discovery World
AUGUST 2, 2023
Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18
Licensing 98
98 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
Janssen Licenses "Flexible Antibody" Technology from F-star in New Collab
BioSpace
OCTOBER 21, 2021
The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.
Licensing 82
82 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.
Antibody 130
130 
Syncromune and Eucure enter antibody licence deal
Pharmaceutical Technology
OCTOBER 19, 2022
Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Syncromune president and CEO Eamonn Hobbs said: “We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen.
Antibody 130
130 
Partnership could enhance antibody discovery for cancer research
Drug Discovery World
JULY 21, 2023
Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post Partnership could enhance antibody discovery for cancer research appeared first on Drug Discovery World (DDW).
Antibody 98
98 
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
MARCH 28, 2023
On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.
Licensing 130
130 
Ipsen licenses ‘cutting-edge’ ADC from Sutro Biopharma in $900m deal
BioPharma Reporter
APRIL 2, 2024
Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.
Licensing 52
52 
Merck Expands ADC Footprint with $9.3B Kelun Licensing Deal
BioSpace
DECEMBER 21, 2022
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Licensing 98
98 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.
Antibody 130
130 
Biogen, aiming for a better Alzheimer’s therapy, licenses a Denali program
Bio Pharma Dive
APRIL 13, 2023
The program is part of Denali’s “transport vehicle” platform, which uses drugmaking technology to shepherd large therapeutic molecules like antibodies across the so-called blood-brain barrier.
Licensing 177
177 
Adcendo and Duality Biologics sign license deal for ADC platform
Pharmaceutical Technology
JANUARY 6, 2023
Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform. The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology.
Licensing 130
130 
US FDA grants fast track designation for Jasper’s antibody to treat SCID
Pharmaceutical Technology
SEPTEMBER 16, 2022
The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. . The antibody was also analysed in a total of more than 110 healthy subjects and patients. .
Antibody 130
130 
ADC licensing deals reached peak of $16.6 billion in 2022
BioPharma Reporter
OCTOBER 26, 2023
The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.
Licensing 59
59 
Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells
BioPharma Reporter
SEPTEMBER 2, 2021
Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.
Antibody 111
111 
Three trends in the antibody-drug conjugate (ADC) market
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.
Antibody 98
98 
Advancing antibody discovery with AI
Drug Discovery World
NOVEMBER 2, 2023
This brought us to intersect with AION Labs, which had issued a call for applicants to launch a new company leveraging AI-based solutions for the computational de novo design of high-affinity antibodies for targeted therapies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.
Antibody 83
83 
Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research
BioTech 365
MAY 10, 2021
Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Antibodies generated by Flow Eighteen38 to be used as research tools by Hubrecht Institute.
Reagent 52
52 
Corbus in licensing deal for monoclonal antibodies to tackle cancer and fibrotic diseases
BioPharma Reporter
JUNE 1, 2021
Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).
Licensing 52
52 
AstraZeneca buys into startup RQ Bio’s COVID antibodies
pharmaphorum
MAY 18, 2022
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on. .
Antibody 98
98 
Biotheus, Hansoh Expand Partnership in $694M ADC Deal
BioSpace
MARCH 14, 2024
Hansoh Pharma is licensing Biotheus’ anti-EGFR/cMet bispecific antibody to develop antibody-drug conjugates. The Chinese biotechs are broadening their collaboration.
Antibody 115
115 
Synaffix secures additional ADC technology licensing deals
BioPharma Reporter
JANUARY 6, 2023
Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.
Licensing 52
52 
AstraZeneca adds to rare disease drug pipeline with Neurimmune deal
Bio Pharma Dive
JANUARY 7, 2022
Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.
Drugs 281
281 
Let's personalize your content